anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Mental fatigue is common in society, but its effects on force production capacities remain unclear. This study aimed to investigate the impact of mental fatigue on maximal force production, rate of force development-scaling factor (RFD-SF), and force steadiness during handgrip contractions. Fourteen participants performed two randomized sessions, during which they either carried out a cognitively demanding task (i.e., a visual attention task) or a cognitively nondemanding task (i.e., documentary watching for 62 min). The mental fatigue was evaluated subjectively and objectively (performances and electroencephalography). Maximal voluntary contraction (MVC) force, RFD-SF, and force steadiness (i.e., force coefficient of variation at submaximal intensities; 25, 50, and 75% of MVC) were recorded before and after both tasks. The feeling of mental fatigue was much higher after completing the cognitively demanding task than after documentary watching (p < .001). During the cognitively demanding task, mental fatigue was evidenced by increased errors, missed trials, and decreased N100 amplitude over time. While no effect was reported on force steadiness, both tasks induced a decrease in MVC (p = .040), a force RFD-SF lower slope (p = .011), and a reduction in the coefficient of determination (p = .011). Nevertheless, these effects were not explicitly linked to mental fatigue since they appeared both after the mentally fatiguing task and after watching the documentary. The study highlights the importance of considering cognitive engagement and mental load when optimizing motor performance to mitigate adverse effects and improve force production capacities.
Stimufend single-dose prefilled syringe for manual use

Stimufend (pegfilgrastim-fpgk) injection is a clear, colorless, preservative-free solution supplied in a pre-filled single-dose syringe for manual use containing 6 mg pegfilgrastim-fpgk, supplied with a 27-gauge, 1/2-inch needle with a Safe'n'Sound® passive Needle Guard. 

The needle cap of the pre-filled syringe contains natural rubber (a derivative of latex). 

Stimufend is provided in a dispensing pack containing one sterile 6 mg/0.6 mL pre-filled syringe (NDC 65219-371-10). 

Stimufend pre-filled syringe does not bear graduation marks and is intended only to deliver the entire contents of the syringe (6 mg/0.6 mL) for direct administration. Use of the pre-filled syringe is not recommended for direct administration for pediatric patients weighing less than 45 kg who require doses that are less than the full contents of the syringe. 

Store refrigerated between 36°F to 46°F (2°C to 8°C) in the carton to protect from light. Do not shake. Discard syringes stored at room temperature for more than 72 hours. Do not freeze. Discard syringe if frozen.
Outpatient colonoscopies are very common, indicated for various reasons, and are more commonly performed in outpatient surgery or endoscopy centers. There is an increase in the use of propofol for sedation because of the short duration of action and quick turn around time. Propofol has been studied extensively for safety and efficacy but patient satisfaction and preference with use has not been well documented in prospective, randomized setting. In the context of the recent changes in healthcare reimbursement where patient satisfaction is becoming an important metric providing data that could improve patient satisfaction is needed.

Patients who presented for a colonoscopy with the Principal Investigator were approached to participate in the study. After obtaining consent the patients were randomized to anesthesia with propofol or control without propofol per random number tables provided by the statistician. The anesthesiologist or nurse anesthetist were asked to remove the paper with the assignment from the envelope to determine which medications to give the patient. Pre-op, intra-op, and post-op data were collected by registered nurses blinded to the anesthetic. The day one follow-up phone call was made by the resident who was blinded to the anesthetic. Data were collected in the pre-op, intra-op, and post-op areas by the researchers who were blinded to the medications used.
The MAPs program is based on experiential training in mindfulness meditation offered at the UCLA Mindful Awareness Research Center (MARC). A certified UCLA instructor will provide didactic training in mindfulness meditation in a group-based setting. Participants will be guided through in-class meditation practices and will be assigned daily meditation homework. Active program components include sitting and walking somatosensory-focused meditation, audio-guided body scan meditation, and loving kindness meditation. Participants will attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary. In addition to the MAPs training, sleep hygiene material will also be presented to match the sleep hygiene material in the sleep education condition.
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating children cough due to wind-cold evil and application thereof. The traditional Chinese medicine composition consists of perilla leaves, asarum, purified pinellia tuber, dried orange peel, poria cocos and dried ginger. The Chinese medicinal composition has effects of warming lung, dispelling cold, eliminating phlegm, and relieving cough. Perillae She Xinwen has effects of dispelling cold, regulating qi-flowing, relieving exterior syndrome, and mild drug property, and is suitable for children, so it is a monarch drug; asarum, herba asari, pungent in flavor and warm in nature, and pinellia ternate, rhizoma Pinelliae, dried Jiang Wenfei, and the like, dry and dispel cold, and the three drugs assist the monarch drugs in warming and resolving phlegm and retained fluid in the lung and are ministerial drugs; dried orange peel, pericarpium citri reticulatae, poria cocos, and the like are used as adjuvant drugs; the dry Jiang Wenfei warms the spleen and also warms the spleen. The whole recipe is combined with the recipe, which has the effects of both dispelling exterior cold evil and warming and resolving phlegm-fluid retention in the lung, and has the actions of warming and resolving cold, resolving phlegm and relieving cough. The composition and the medicine prepared by the composition can effectively treat children cough due to wind-cold evil.
PURPOSE: A composition including a Scrophulariae Radix extract having excellent activity on inhibiting cell senescence in cell culture of cell lines of human fibroblast as well as in an experimental animal model is provided. It can deter senescence and prevent geriatric diseases. CONSTITUTION: The composition contains an extract of Scrophulariae Radix(Scrophularia buergeriana Miq.) which is extracted with water or an organic solvent. For an example, 100g Scrophulariae Radix is finely ground, extracted in ethanol for 2hr at 50deg.C and concentrated after complete removal of ethanol components. The Scrophulariae Radix extract exhibits delaying senescence in vivo as well as in vitro cell culture.
A preparation method of a 4D chitosan-based thermosensitive hydrogel. Chitosan is dissolved in acetic acid solution and then printed by a 4D bioprinter into a chitosan-based thermosensitive hydrogel with a pore size of 50-100μm. This is then lyophilized after solvent extraction. Subsequently, aqueous solutions of β-sodium glycerophosphate and aqueous carboxymethyl chitosan are prepared with ultrapure water; the aqueous β-sodium glycerophosphate solution is charged into and mixed well with the aqueous carboxymethyl chitosan solution to prepare a mixture. Finally, the lyophilized chitosan is crosslinked with the mixture to obtain the 4D chitosan-based thermosensitive hydrogel. The hydrogel can be used in corneal wound healing, particularly in the repair of corneal alkali burns. In one embodiment, limbal stem cells are entrapped in the hydrogel and then applied on the surface of an alkali burned cornea such that the limbal stem cells are released to repair and treat the wound.
NEW MATERIAL:Clavularin A shown by the formula. USE:To be expected as a carcinostatic agent. PROCESS:Frozen and stored Clavularia viridis Quoy & Gaimard is stirred and extracted twice with methanol, the residue is extracted with methylene chloride, and both the extracted solutions are concentrated. The prepared concentrated residue is dissolved in methylene chloride again, impurities are removed, and a filtrate is concentrated. The concentrated filtrate is adsorbed on a silica gel column, eluted with chloroform-methanol, a fraction having a cell toxicity is collected, the fraction is adsorbed on a gel filtration column, and eluted. The fraction having the cell toxicity is adsorbed on a silica gel thin layer chromatography plate, an ultraviolet-absorbing band showing a Rf of about 0.6 when it is developed with chloroform-methanol is eluted, and concentrated to give raw Clavularin A. The raw Clavularin A is adsorbed on the silica gel thin layer chromatography plate, developed with n-hexane-ethyl acetate to give the desired high-purity substance purer than a band having a Rf of about 0.4.
Systems and methods for conducting respiratory therapy in a respiratory system can adjust a flow of respiratory gases to a patient based upon a detected patient breath cycle. The respiratory system can include a non-sealed patient interface. The respiratory system can be configured to deliver a high flow therapy. The system can synchronize the flow rate with the detected breath cycle of the patient. The amplitude of the flow rate variation can be based partially on a value selected by the user. The adjustments to the flow rate can be done by controlling the motor speed using a positive feedback system. The adjustments to the flow rate can also be limited by the controller preventing the flow rate from crossing a minimum and/or maximum threshold.
FIELD: pharmaceutical technology. SUBSTANCE: invention relates to new analgetic drug. Analgetic agent has the following composition at mole ratio: procidol 1.0; ethyl alcohol 1660.0; glycerol 440.0; citric acid 2.0; monosubstituted sodium citrate 2.0; sodium chloride 5.7, and water for injection 34.2 l up to the total volume (pH is 3.4-4.0). The claimed method of preparing the indicated composition involves mixing water, ethyl alcohol, glycerol, propylene glycol, citric acid, hydrochloric acid and sodium hydroxide and procidol (1-(2-ethoxyethyl)-4-phenyl-4-propionylhydroxypiperidine hydrochloride) is added to obtained solution. Components are taken at amount to provide pH value at the range 3.4-4.0. Then solution is filtered through sterilizing filter under aseptic conditions followed by its pouring in ampoules in atmosphere of inert gas, for example, nitrogen. Hydrochloric acid and sodium hydroxide are used as 1M solutions. Method ensures to obtain composition exhibiting stability under usual storage conditions and prolonged fitness time as compared with that of the known preparation - 1% procidol an aqueous solution (2 years at +5 C). EFFECT: improved quality, property and a method of preparing. 3 cl, 1 ex, 1 dwg
2-Amino benzimidazole derivs. of formula (I), in which R1 and R2 can be various radicals are made by reacting an amino-benzimidazole cpd. (III) with a halogenated deriv. of formula (II) in presence of an alkalie amidide dissolved in liq. ammonia, or n-butyl lithium dissolved in an ether solvent, with stirring at ambient temp. The prod. is isolated and purified by conventional methods.
PROBLEM TO BE SOLVED: To obtain a synthetic product useful for preservating and storing interal organs prior to the transplantation to patients who need the transplantation by containing a specific compound and calcium in a physiologically acceptable preservative liquid for external use for internal organs. SOLUTION: This physiological acceptable preservative liquid for external use for internal organs contains taxol of the formula and calcium in a preservative liquid or a sprinkling liquid for internal organs or in a heart-paralytic drug. Further, it possesses a capacity osmolarity of about 320mOsm/l and taxol, calcium and lactobionic acid salt may be contained in the preservative liquid. This preservative liquid possesses a molecular weight of about 150,000Da to about 350,000Da and is preferably composed of substantially ethylene glycol, ethylene chlorohydrin, sodium chloride and about 3-8wt.% of hydroxyethyl starch containing no acetone. Taxol is preferably covered with liposome. Taxol and calcium are contained in amounts of about 1nM to about 100nM and about 0.5μM to 1.5μM, respectively.
PROBLEM TO BE SOLVED: To obtain a new oxazole derivative having an excellent insulin secretion-stimulating action and an excellent hypoglycemic action, useful as a diabetes-treating medicine and low in toxicity. SOLUTION: This compound is represented by formula I (R<1> is a halogen, a heterocyclic group, hydroxy, thiol, etc.; A is an acyl, a heterocyclic group, hydroxy, carboxy which may be esterified or amidated; B is an aromatic group; Y is a divalent aliphatic hydrocarbon) or its salt, e.g. 4-(4-chlorophenyl)-2-(2- methyl-1-imidazolyl)-5-oxazole propanol or its salt. The compound of formula I is obtained e.g. by reacting a compound of formula II or its salt with a halogenating agent. Thereby, good insulin secretion-stimulating medicines, diabetes-preventing and treating medicines, antihypertensive agents, etc., can be obtained from the compound of formula I.
BACKGROUND: Although many studies on the association between dyslipidemia and cardiovascular disease (CVD) exist in older adults, data on the association among adolescents and young adults living with disproportionate burden of cardiometabolic disorders are scarce.
METHODS AND RESULTS: The SHFS (Strong Heart Family Study) is a multicenter, family-based, prospective cohort study of CVD in an American Indian populations, including 12 communities in central Arizona, southwestern Oklahoma, and the Dakotas. We evaluated SHFS participants, who were 15 to 39 years old at the baseline examination in 2001 to 2003 (n=1440). Lipids were measured after a 12-hour fast. We used carotid ultrasounds to detect plaque at baseline and follow-up in 2006 to 2009 (median follow-up=5.5 years). We identified incident CVD events through 2020 with a median follow-up of 18.5 years. We used shared frailty proportional hazards models to assess the association between dyslipidemia and subclinical or clinical CVD, while controlling for covariates. Baseline dyslipidemia prevalence was 55.2%, 73.6%, and 78.0% for participants 15 to 19, 20 to 29, and 30 to 39 years old, respectively. Approximately 2.8% had low-density lipoprotein cholesterol ≥160 mg/dL, which is higher than the recommended threshold for lifestyle or medical interventions in young adults of 20 to 39 years old. During follow-up, 9.9% had incident plaque (109/1104 plaque-free participants with baseline and follow-up ultrasounds), 11.0% had plaque progression (128/1165 with both baseline and follow-up ultrasounds), and 9% had incident CVD (127/1416 CVD-free participants at baseline). Plaque incidence and progression were higher in participants with total cholesterol ≥200 mg/dL, low-density lipoprotein cholesterol ≥160 mg/dL, or non-high-density lipoprotein cholesterol ≥130 mg/dL, while controlling for covariates. CVD risk was independently associated with low-density lipoprotein cholesterol ≥160 mg/dL.
CONCLUSIONS: Dyslipidemia is a modifiable risk factor that is associated with both subclinical and clinical CVD, even among the younger American Indian population who have unexpectedly high rates of significant CVD events. Therefore, this population is likely to benefit from a variety of evidence-based interventions including screening, educational, lifestyle, and guideline-directed medical therapy at an early age.
The safety and effectiveness of ARAVA in pediatric patients have not been established. 

The safety and effectiveness of ARAVA in the treatment of polyarticular course juvenile idiopathic arthritis (JIA) was evaluated in a single multicenter, double-blind, active-controlled trial in 94 pediatric patients (1:1 randomization) with polyarticular course juvenile idiopathic arthritis (JIA) as defined by the American College of Rheumatology (ACR). In this population, ARAVA treatment was found not to be effective. 

The safety of ARAVA was studied in 74 patients with polyarticular course JIA ranging in age from 3–17 years (47 patients from the active-controlled study and 27 from an open-label safety and pharmacokinetic study). The most common adverse events included abdominal pain, diarrhea, nausea, vomiting, oral ulcers, upper respiratory tract infections, alopecia, rash, headache, and dizziness. Less common adverse events included anemia, hypertension, and weight loss. Fourteen pediatric patients experienced ALT and/or AST elevations, nine between 1.2 and 3-fold the upper limit of normal, and five between 3 and 8-fold the upper limit of normal.
Obsessive-compulsive disorder (OCD) is an anxiety disorder that is associated with recurring repetitive behaviors and persistent unwanted thoughts. People with OCD often carry out ritual-like behaviors such as counting, cleaning, or washing their hands in order to momentarily ease their anxiety. A current treatment for people with OCD is the class of antidepressants called selective serotonin reuptake inhibitors (SSRIs). A recent re-analysis of clinical trials on children with psychiatric conditions found that the risk of suicidal thoughts and behavior when on SSRI-antidepressants was considerably higher than when on placebo. The data also revealed that antidepressant-associated suicidal behavior was not limited to children with depression, but also affected children with OCD and other anxiety disorders. Although the process responsible for increased suicidality is unknown, it may be initiated by a set of symptoms collectively called SSRI induced activation syndrome, which is thought to be common, particularly in children and teens. However, there is a lack of knowledge on this syndrome, including its role in suicidal behavior and how it can be prevented. This study will evaluate a new behavioral test to measure certain side effects linked to antidepressant use. This study will also evaluate the effectiveness of the SSRI sertraline plus cognitive behavioral therapy (CBT) to treat people with OCD.

Potential participants will undergo an initial screening visit that will include an interview on psychological symptoms associated with OCD and possible family history of OCD. Eligible participants will then undergo a physical exam, blood draw, DNA sampling, and pregnancy test if applicable. Participants will be randomly assigned to receive either sertraline or placebo daily for 18 weeks. At weekly study visits, participants will receive their study drug, complete questionnaires about symptoms of OCD, and undergo vital sign measurements. At specified visits, participants will also perform a task (Stop Signal Task) on a computerized assessment device to measure attention and impulse control and may have blood drawn. For the first 4 weeks participants will wear a wristwatch-like device (actigraph) to monitor sleep patterns. During the first three visits, participants will receive supportive psychotherapy. At Visit 4, participants will begin receiving 60-minute CBT sessions, which will continue until the final visit. The final visit will include a second physical exam, questionnaires, and blood testing.
Background: Preeclampsia is a leading cause of pregnancy-related maternal and fetal morbidity and mortality. Although its precise cause and prevention remain unclear, risk factors such as overweight and inadequate nutrient intake (e.g., calcium, folic acid, and vitamin D) are known to increase its incidence. Recent research has focused on the genetic predisposition to preeclampsia, identifying polymorphisms that may affect enzyme or receptor function. This study aims to review existing literature examining the relationship between genetic polymorphisms, BMI (body mass index), and nutrient levels in preeclampsia to develop more actionable therapeutic strategies. Methods: A systematic review was conducted to analyze studies on the nutrigenetic relationship between BMI, micronutrients, and preeclampsia. Results: A total of 17 studies investigating 12 genes related to BMI and 10 studies exploring 3 genes in relation to micronutrient levels were included in the analysis. Several polymorphisms associated with preeclampsia were found to be influenced by maternal BMI or serum vitamin levels. The interactions between certain gene variants and these factors suggest that both BMI and micronutrient status may modify the risk of developing preeclampsia in genetically predisposed individuals. Conclusions: Our findings emphasize the potential for reanalyzing existing data by categorizing based on genotype and nutrient levels. This approach could yield more personalized dietary and therapeutic recommendations for managing preeclampsia. In the future, genetic information may support the development of tailored nutritional counseling during pregnancy to mitigate preeclampsia risk.
The Onco-Seraph 100 Filter is a single use, disposable column packed with ultra-high molecular weight polyethylene beads which have been modified to contain endpoint attached heparin on the surface. The devices are sterilized using a standard ethylene oxide cycle, following ISO 11135:2014/A1:2018. Chemical Indicator labels are located near the product label. A green label indicates that the device has been exposed to ethylene oxide gas. Onco-Seraph 100 is part of the Seraph platform technology that was also developed as an extracorporeal broad-spectrum sorbent hemoperfusion device for reduction of pathogens from the bloodstream.